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Cyclosporin is a metabolite isolated from culture broths of the fungus Tolypoclad-
ium inflatum Gams which was shown to be immunosuppressive by Borel et al. in 
rats, mice and guinea-pigs.1.2 Cyclosporin may directly block the release of 
interleukin I from activated T helper cells and indirectly block the release of 
interleukin II from macrophages, thus suppressing both cellular and humoral 
immunity. The drug is most effective if given at the time of immunization or, -
antigenic challenge, but the suppressive effect is reversible. These effects are not 
accompanied by bone marrow depression, and do not lower resistance to bacterial 
and fungal infections. There is some doubt about the effect of cyclosporin on viral 
infections. 
When cyclosporin was first used in patients by Caine et al. 3 in 1978, it was hoped 
that no other drug would be routinely required. However, most of their experience 
has been with delayed administration of the drug because of the fear of 
nephrotoxicity and hepatotoxicity. Azathioprine and prednisone were used initially 
until renal and hepatic functions were adequate. Then l:yclosporin was begun, and 
the steroid dose was slowly reduced and withdrawn. 4 The supervention of acute 
rejection during treatment with azathioprine and prednisone was troublesome. 
In late 1979, cyc1osporin became available for preliminary testing in the USA. 
The authors' initial experience in cadaver renal transplantation5 1ed them to believe 
that the combination of cyclosporin and steroids is a more effective and safe 
immunosuppressive treatment than cyclosporin alone. From then until the end of 
1984, approximately 500 cadaver renal,6 300 hepatic,7 100 cardiac and 10 pancreatic 
transplants were carried out at the University Health Centre of Pittsburgh under 
cyclosporin-steroid treatment. The authors' experience is briefly summarized here 
as an example of the use of cyclosporin. 
Basic treatment 
Cyclosporin: if there are several hours in which to prepare a patient for organ 
transplantation, cyclosporin, 17.5 mg/kg body weight, is administered orally as an 
initial loading dose. After this, cyclosporin is generally not given until the operation 
is completed. If there is not enough time for digestion of the drug before surgery. 
cyclosporin, 2 mglkg body weight, is administered intravenously over 2-3 hours 
after the revascularization of the graft. The dose is repeated every 8 hours, 
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provided the patient is haemodynamically stable and producing an adequate 
amount of urine. 
After surgery, kidney recipients can usually resume oral intake within 12-24 
hours. They receive oral cycJosporin, 17.5 mg/kg body weight/day in two divided 
doses, and the trough level of cyclosporin is monitored carefully. Liver recipients 
can usually resume oral intake a few days after the transplant operation. Although 
they receive oral cycJosporin, 17.5 mg/kg body weight/day in two divided doses, as 
soon as can be tolerated, intestinal absorption of the drug is usually poor for a few 
weeks. Therefore, during this early postoperative period. cyclosporin is adminis-
tered intravenously as well as orally (double route therapy) in order to maintain 
adequate levels of the drug. An adequate blood level is achieved when the trough 
level of cyclosporin is 800-1000 nglml of whole blood measured by radioimmuno-
assay, or 150-300 nglml measured by high performance liquid chromatography. 
When an adequate blood level of the drug is achieved by administering double 
route therapy, the intravenous dose of cycJosporin is gradually reduced and then 
discontinued. Commonly, the oral dose required to maintain an adequate drug 
level is greater than 17.5 mg/kg body weight/day (Figure 1). 
The mean maintenance dose of oral cycJosporin 1 month after liver transplan-
tation is 12.5 ± 4.3 mg/day for adults and 17.1 ± 3.9 mg/day for small children 
(Figure 2). 
Corticosteroid treatment with methylprednisolone, 1 g i.v., begins immediately 
before revascularization of the graft. After surgery, a 5-day burst of prednisone or 
methylprednisolone is started at 200 mg/day. This dose is reduced daily by 
40 mg to an initial maintenance dose of 20 mg/day for adults (Figure 1). In children, 
intravenous methylprednisolone, 250 or 500 mg, is given before revascularization. 
After the operation, a 5-day burst of prednisone or methylprednisolone is begun at 
Time Cyclosporin regimen Steroid regimen 
Before 2 mg/kg body weight i.v. or 
transplantation 17.5 mg/kg body weight p.o. 
Day of 2 mg/kg body weight i.v. Methylprednisolone, 1 g i.v. 
transplantation every 8 hours 
Day1 (the dose may be increased Methylprednisolone, SO mg i.v. 
inthe presence of uraemia every6hours 
or high trough levels) 
Day2 (the dose may be increased Methylprednisolone, 40 mg i.v. 
in the presence of uraemia or every6hours 
high trough levels) 
Day3 3 mg/kg body weight i.v. Prednisone, 30 mg p.o. every 
every 12 hours and 17.S 6 hours 
mg/kg body weight p.o. in 
2 divided doses 
Day4 (i.v. dose decreased as Prednisone, 20 mg p.o. every 6 hours 
Day5 the intestinal absorption Prednisone, 20 mg p.o. every 12 hours 
Day6 increases and an adequate Prednisone, 20 mg p.o. every 24 hours 
Day7 blood level is achieved) 
1 Basic cyclosporin and low-dose steroid treatment. 
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Patients Daily cyclosporin dose (mg/kg body weight) 
1 month 3 months 6months 9months 12months 
Adults (>40 kg) 12.5±4.3 10.8 ± 6.7 8.2±3.6 7.6±3.5 6.7 ± 2.2 
School-aged 12.7±3.1 12.1 ± 5.6 10.5 ± 2.8 9.8±3.6 8.9± 2.7 
children 
(21-40 kg) 
Pre-school-aged 17.1 ± 3.9 17.8± 5.6 14.7 ± 5.3 12.1 ± 3.8 11.1 ±2.2 
children 
«20kg) 
2 Daily oral cyclosporin dose in both adults and children to avoid nephrotoxicity at 
1,3,6,9 and 12 months after liver transplantation. 
100 mglday; this dose is reduced by 20 mglday to an initial maintenance dose of 
10 mg/day. A further reduction in steroid dose is made in small children and infants. 
The maintenance dose of prednisone at 1 month is 15-20 mg/day for adults and 
5-15 mg/day for children. Further reduction of prednisone dose depends on graft 
function. 
Treatment for rejection 
If rejection occurs despite cyclosporin and low-dose steroid treatment, the course 
of action is the same as with conventional immunosuppressive treatment, that is, to 
administer large doses of intravenous hydrocortisone or methylprednisolone 
intermittently (pulse therapy). repeating the original 5-day burst of prednisone 
(recycle), and setting a higher maintenance dose of steroids. Although cyclosporin 
does not permit much dose manoeuvrability because of its toxicity, it is sometimes 
possible to increase the doses given orally or intravenously. 
Antilymphocyte globulins (ALG) or monoclonal antibodies have been used 
occasionally for steroid refractory rejections. 
Case 1 - RA was a 20-year-old female patient who received a cadaver renal 
transplant for the first time. The clinical course is summarized in Figure 3. She was 
given basic oral treatment. The renal graft functioned immediately. On day 7, an 
acute rejection episode was diagnosed. She received methylprednisolone, 1 g Lv., 
and a 5-day burst of oral prednisone. With this anti-rejection therapy, the acute 
rejection crisis was reversed. However, on day 14, she developed pneumonitis and 
was placed on a respirator for a few days. She recovered from pneumonitis after 
1 week, but her renal function deteriorated during the infection because the 
immunosuppressive therapy was drastically reduced to overcome the life-
threatening infection. During the fourth week, she received hydrocortisone. 1 g 
i.v., twice, with no improvement in renal function. On day 26. monoclonal 
antibodies (OKT-3) were given and continued for 2 weeks. With OKT-3 treatment 
and an increased dose of cyclosporin. the second rejection episode was completely 
reversed. without an increase in the basic steroid dose. 
Case 2 - RM was a 5-year-old boy who received an orthotopic liver transplant for 
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OKT-3 = monoclonal antibodies, s.c. = hydrocortisone sodium succinate 
s.m. = methylprednisolone hemisuccinate. 
biliary atresia after a failed Kasai hepatic porto-enterostomy. Before the first and 
the second liver grafts he was prepared with basic intravenous treatment. His 
clinical course is summarized in Figure 4. The first liver graft was lost through 
hepatic artery thrombosis and the second graft was transplanted 15 days after the 
first. Acute rejection of the second graft occurred in the third week. It was treated 
with hydrocortisone, 1 g i. v., pulse therapy, followed by a 5-day burst of oral 
prednisone without success. Antithymocyte globulin (A TG) was then administered 
intravenously for 2 weeks, resulting in resolution of the rejection crisis. During the 
course of treatment, the patient's cyclosporin dose was adjusted..on the basis of 
trough levels of the drug. 
Side-effects of cyclosporin 
Side-effects of cyclosporin include: 
• nephrotoxicity 
• hepatotoxicity 
• acidosis 
• hypertension 
• convulsions 
• lymphomas 
• gum hyperplasia 
• hirsutism 
• tremor 
• flushing 
• paraesthesia. 
These side-effects are generally related to the dose used and can be corrected by 
reducing the dose or discontinuing treatment. 
S Iwatsuki et al. 
JKT-3 
~ ....... ~ 
~ 
35 42 
...J 
49 
Time (days) 
n succinate 
Before the first and 
JOUS treatment. His 
Jft was lost through 
ed 15 days after the 
week. It was treated 
5-day burst of oral 
1S then administered 
on crisis. During the 
sted on the basis of 
.::an be corrected by 
Use of cyclo sp orin 
Alanine 
aminotransferase 
IIU/litre) 
Bilirubin 
(mg/dll 
Cyclosporin blood level 
lng/mil 
I Radioimmunosassay) 
Cyclosporin dose 
Img/day p.o.) 
Cyclosporin dose 
(mg/day Lv.) 
Prednisone dose 
(mg/day) 
Fever 
Septicaemis 
1000 
500 
200 
100 ~~ 
lr-----~~r-------------------
15 
10 
~~~~----~~~~~= 
2000 • 
1000 
l~----~------------~-r----
400 
l~~~nh~~~~--~~~~~ 
100 
l~~~~~~--~--~----100 s. 
50 
l~~~"""""""~ o 15 30 45 60 75 
First Second 
transplant transplant Time Idays) 
147 
4 Case 2: an example of acute hepatic graft rejection. ATG=antithymocyte globulin, 
s.m. and s.c. - see legend for Figure 3. 
Nephrotoxicity: acute nephrotoxicity of cyclosporin was recognized in the earliest 
clinical studies on kidney transplantation,1.5 and was confirmed in liver 
transplantation,8 bone marrow transplantation and cardiac transplantation. The 
toxicity can lead to oliguria or anuria and prolong the period of acute tubular 
necrosis (A TN). CaIne et 01.4 recommended delaying the administration of the first 
dose of cyclosporin until post-transplant diuresis was established" conventional 
treatment (azathioprine and prednisone) being used before then. The authors have 
been starting cyc1osporin treatment immediately before transplantation and 
continuing it, regardless of the immediate renal graft function; the dose is adjusted 
on the basis of the blood level of the drug. Although this practice may prolong the 
period of A TN, it is better for controlling acute rejection which may occur during 
the an uric phase of A TN . 
Case 3- RC was a 53-year-old male patient who received a second cadaver renal 
graft. He was moderately sensitized after losing the first graft from rejection. The 
second graft was stored in cold Collins solution for 36 hours and initial renal 
function was poor. A renal scan indicated A TN with excellent blood flow. Oral 
basic therapy was begun before transplantation and was continued through the 
period of A TN; the dose of cyc\osporin was adjusted on the basis of the blood level 
of the drug (Figure 5). Because the patient was moderately sensitized, intravenous 
steroid pulse therapy was given at 5-day intervals during the anuric phase to 
prevent or treat rejection masked by A TN. Despite the continuous use of 
cyc1osporin. diuresis began after 2 weeks and haemodialysis was discontinued after 
3 weeks. The patient's serum creatinine level returned to normal 40 days after 
transplantation. 
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5 Case 3: the use of cyclosporin during acute tubular necrosis (ATN). 
0= dialysis, s.m. and s.c. - see legend for Figure 3. 
Some renal toxicity was observed in the majority of liver recipients who were 
treated with cyclosporin and low-dose steroid treatment. However. less than a few 
percent of the last 300 recipients required haemodialysis following liver transplan-
tation. Most of the patients had renal failure before transplantation or had been 
very unstable haemodynamically. 
Renal toxicity: The cause of postoperative anuria or oliguria is generally pre-renal 
in liver transplantation. However. postoperative renal failure can be exacerbated 
by cyclosporin nephrotoxicity. When anuria or oliguria persists despite adequate 
volume replacement and cardiac support, a brief reduction in the dose of 
cyclosporin is recommended. Following dose reduction. the urine volume increases 
and renal function improves; the dose of cyclosporin can then be gradually 
increased to the basic treatment level. If the recipient requires haemodialysis, the 
cyclosporin dose is reduced to maintain the trough level of the drug in the lower 
ranges (500-800 ng/ml of whole blood measured by radioimmunoassay) until renal 
function recovers. 
Mild renal impairment manifested by slightly elevated blood urea nitrogen levels 
and serum creatinine levels is commonly seen later in the post-transplant period. 
Often, the dose of cyclosporin is maintained at a relatively high level in the 
presence of mild rejection. Gradual reduction of the dose usually improves the 
renal function. Interstitial fibrosis of the kidney has been reported in cardiac 
transplant9 and in renal transplant lO after long-term use of cyclosporin. This 
fibrosis seems to be caused by a relatively high dose of cyclosporin administered 
during the 6 months following transplantation. The maintenance doses of oral 
cyclosporin required to avoid nephrotoxicity in liver transplant patients at 1. 3, 6. 9 
and 12 months are given in Figure 2. Small children and infants can tolerate higher 
doses of cyclosporin than adults. 
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Hepatotoxicity of cyclosporin is an uncommon side-effect and is generally mild. It 
can manifest clinically both in hepatocellular injury form and in cholestatic form. 
The clinical differentiation of cyclosporin hepatotoxicity from viral hepatitis, mild 
bile duct obstruction, other drug toxicity and graft rejection in liver transplants is 
difficult, even with liver biopsy. When cyclosporin hepatotoxicity is suspected, it is 
worthwhile reducing the dose of cyclosporin briefly to observe the response, 
particularly in the presence of high trough levels of the drug. Only careful analyses 
of chemical, serological and histological studies can lead to a proper diagnosis. 
Fortunately, cyclosporin hepatotoxicity is much less troublesome in the manage-
ment of patients than nephrotoxicity. 
Lymphomas and lymphoproliferative lesions: the incidence of post-transplant 
lymphoma is probably less with cyclosporin-prednisone treatment than with 
azathioprine-prednisone-ALG treatment. 11 Epstein-Barr virus infections are 
generally associated with the development of these lesions. Fever, malaise and 
lymphadenopathy are the usual clinical manifestations. Acute abdominal symp-
toms, such as perforation, obstruction, bleeding or diarrhoea, also develop when 
intestinal lymph nodes are affected. 
When lymphoma is confirmed by pathological examination, or when it is 
suspected on the basis of clinical manifestations, drastic reduction or discontinu-
ation of immunosuppressive drugs (both cyclosporin and prednisone) is mandatory 
to overcome the otherwise fatal lesions. The results of anti-neoplastic chemotherapy 
for this type of lymphoma are much worse than those caused by discontinuation of 
immunosuppressive treatment. Antiviral chemotherapy alone cannot cure this 
lesion. Early recognition of lymphoproliferative lesions is vital and the subsequent 
drastic reduction of immunosuppressive therapy is the treatment of choice. The 
grafts commonly suffer from rejection during this period of drastic reduction of 
immunosuppressive treatment, but most grafts recover from rejection when the 
immunosuppressive treatment is restored following the disappearance of the 
lymphomas. 
Case 4- KH was a 2-year-old girl with biliary atresia who received an orthotopic 
liver transplant after a failed Kasai operation. She was initially given basic 
intravenous treatment, and then double route therapy. After 3 weeks, cyclosporin 
was administered by the oral route alone (Figure 6). The dose was well-adjusted by 
monitoring renal function and the blood levels of the drug. She had two episodes of 
acute rejection, 1 week and 6 weeks after transplantation. Both rejection crises 
were. successfully reversed by intravenous steroid pulse therapy and increasing the 
dose of oral prednisone. Approximately 10 weeks after transplantion, the patient 
developed fever, malaise, loss of appetite and enlargement of the tonsillar glands 
causing partial airway obstruction. Despite intensive intravenous antibiotic 
treatment she remained febrile, and the signs of airway obstruction worsened. 
Tracheostomy and tonsillectomy were performed on an urgent basis. 
Pathological examination of the enlarged tonsillar glands confirmed the diagnosis 
of lymphoma. The doses of both cyclosporin and prednisone were reduced to half 
their previous levels and antiviral chemotherapy (acylovir) was given for 10 days. 
The patient became afebrile and all the signs and symptoms of lymphoproliferative 
lesions subsided in 10 days. Three weeks later, the dose of cyclosporin was restored 
to the previous level. There was no rejection of the liver graft despite a drastic 
reduction in immunosuppressive therapy for 3 weeks. 
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6 Case 4: an example of lymphoma, successfully treated by drastic 
reduction of immunosuppression, s.m. and s.c. - see legend 
for Figure 3. 
Conclusion 
Cyc\osporin is the most effective immunosuppressive agent available today. and is 
more effective and safe when used with low doses of corticosteroids. Some of its 
side-effects are troublesome and serious. Measurements of drug concentrations in 
the blood or serum can provide a useful guide to the proper use of cyc\osporin. 
However, the drug level and the toxicity do not correlate in many instances. nor do 
the drug level and the immunosuppressive activity of the sera obtained from the 
individuals who are taking cyclosporin. A great deal of information is to be learned 
as experience with this drug extends rapidly. 
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